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Purpose: This study was designed to evaluate the relative efficacy of various brands of 
ivermectin injection available for use in clinical veterinary practice in Nigeria. 
Method: Ivermectin injections were evaluated by a larval development assay (LDVA), using 
the larvae of Strongyles (predominantly Haemonchus contortus) of sheep. The effect of 
standard solutions of the drug from the various brands on the transformation of L1 to L3 and 
survival of L3 larvae was used to assess bioactivity. The 50% lethal concentration (LC50) was 
determined from regression line obtained by probit transformation of the biological data. The 
LC50 values for each of the brands were compared with that of the innovator brand (Ivomec 
Super) for any significant difference. 
Results: The LC50 values obtained for the five brands varied widely. It ranges from 1.1±0.17 
ng/ml for the innovator brand to 2.3±0.3, 3.0±0.3, 8.0±0.2 and 17.0±0.3 ng/ml for the other 
four brands. The biological assays performed on each of the five brands were of comparable 
precision. LC50 for Ivomec super was significantly different from those of the other four 
brands (Student’s t test, p < 0.01). 
Conclusion: The bioactivities of brands of ivermectin injections available in Nigeria are 
significantly different. This is a probable reason for the varied treatment response to various 
brands of ivermectin injection in veterinary practice in Nigeria. This justifies the need for drug 
regulatory bodies in Nigeria to ensure that ivermectin injections registered for use in Nigeria 
meets approved standards before the drugs are allowed to be imported into the country.  
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Introduction 
 
Ivermectin is an analogue of avermectin, 
which belongs to a family of 16-membered 
macrocyclic lactones. It is known to increase 
membrane permeability to chloride ions 
possibly as a result of their interaction with 
chloride ion channels1. Its broad spectrum of 
activity and wide safety margin has made it 
the drug of choice for nematode and 
arthropod parasitism in cattle, sheep, goat, 
swine and horses2.  However, farmers and 
clinicians in Nigeria have observed wide 
variation in treatment response with different 
brands of Ivermectin injection against endo- 
and ecto-parasites of animals. This often 
results in poor helminth control and 
sometimes treatment failure, with the 
consequent economic loss.  
 
The availability of different formulations of 
the injection from various manufacturers 
warrants the comparative evaluation of 
bioactivity of the various brands in Nigerian 
market. In this paper therefore, we describe 
the comparative anthelmintic activity of 
various brands of ivermectin injection against 
gastrointestinal nematode of sheep, using a 
larval development assay. 
  




The nutritive medium was as described by 
Hubert and Kerboeuf4. It is composed of 
Earle’s balance salt solution plus yeast 
extract diluted in saline solution  (1 gm yeast 
extract in 90 ml of saline solution).  
 
Preparation of ivermectin solution  
 
The ivermectin injection brands investigated 
are Iverject® (Batch No. 349590, Special T. 
Product, UK), Ivomec Super® (Batch No. HN 
00270, MSD, Merial, Netherlands), 
Kepromec® (Batch No. 0IJ15, Kepro B.V, 
Holland), Ivojec (Batch No. 2001.12, 
Sinochem Ningbo, China), and Ivermectin® 
(Batch No. 2531, Anupco, UK). Appropriate 
aliquots of these drugs were taken from 
different stock aqueous solutions (1000 
ng/ml, 100 ng/ml and 10 ng/ml) of drug 
prepared from the injection (apart from 
Ivomec super® which contains 10% 
clorsulon in addition to the ivermectin labeled 
content, the other brands of ivermectin 
injections contain 1% w/v solution of 
ivermectin in propylene glycol). The final 
concentration in the assay tubes were over 
the range of 0.2 – 60.0 ng/ml of ivermectin. 
 
Nematode Egg Recovery Technique  
 
The technique used was that previously 
described by Prichard3. Briefly, 10-15 g of 
faeces of sheep was suspended in water 
and cleared of organic debris by filtration 
through sieves (1mm and 100 µm) and the 
eggs were collected on a 20 µm sieve. 
These eggs were further cleared from 
organic debris by centrifugation in 
magnesium sulphate (density 1.10) for 5 min 
at 1000 g. The supernatant was filtered 
through 100 µm and 60 µm sieves and the 
eggs were washed in water and collected on 
a 20 µm sieve.  
 
The concentration of eggs was estimated in 
50 µl samples and adjusted to 100 – 120 
eggs/ml. The egg suspension was diluted 
with the filtrate from the first step of egg 
extraction (described above) in order to 
provide rumen bacteria necessary for 
nematode larvae development. To avoid the 
proliferation of fungi, 5 µg of amphotericin B 
was added per ml of egg suspension. 
 
Larval development viability assay (LDVA) 
 
Using a 5-ml test tube, 150 µl of nutritive 
medium was added to 50 µl of egg 
suspension containing approximately 100 
eggs. Three replicates per concentration or 
water (control) were made. The tubes were 
covered and put in an incubator at 29 oC, for 
48 hr to allow development of the parasite to 
first stage larvae. Appropriate aliquots of the 
drug was then added. The third stage larvae 
Ademola et al., 2003                    Ivermectin and sheep nematodes 
Trop J Pharm Res, December 2003; 2 (2) 237 
were obtained seven days later. At this time, 
the parasite was counted by separating the 
larvae in to two classes, living third stage 
larvae (L3) and dead larvae. Larval 
development parameter is given by: 
 
No. of Living L3/total no. of nematode in tubes 
with anthelmintic divided by no. of living 
L3/total number of nematode in control tube 
(water).  
 
Statistical analysis  
 
Data from LDVA were transformed by probit 
transformation and plotted against the 
logarithm of concentration7. Probit trans-
formation was performed to transform a 
typical sigmoid dose-response curve to a 
linear function. The concentration required 
to kill 50% of L3 (LC50) was calculated from 
this linear regression scale.   
 
Relative bioactivity of the various brands 
was determined by comparing the mean 
LC50 of each of the other brands with the 
LC50 for Ivomec Supe using a Student t-test 
(2-tailed) at 95% confidence interval. 
Probability (p) values < 0.01 was considered 
to be significant5. 
 
Results and Discussion 
  
A linear relationship was observed between 
larval survival and drug concentration for the 
various brands of ivermectin injection (Figure 
1). The calculated LC50 of Iverject, Ivomec 
super, Kepromec, Ivojec and Ivermectin 
were 2.3 ng/ml, 1.1 ng/ml, 8.0 ng/ml, 17.0 
ng/ml and 3.0 ng/ml, respectively. The result 
of the comparison of the bioactivity of the 
various injection brands with Ivomec super is 
as shown in the Table 1. 
 
The results show variation in the bioactivity 
(LC 50) of the brands of Ivermectin injection 
investigated, ranging from 1.1 ng/ml to 17 
ng/ml. In a previous work, Ademola6 
reported varying LC50 (0.79-4.0 ng/ml) for 
Ivomec MSD against strongyles of sheep 
from different farms in Oyo State, Nigeria. In 
another report7, it was shown that 
Weybridge strain of Haemonchus contortus 
is more susceptible (LC50 – 0.4 ng/ml) than 
the Australian strain (LC50 – 8.9 ng/ml) to 
ivermectin (Ivomec MSD). An ivermectin 
resistant strain of H. contortus was also 
reported to have LC50 of 8.0 ng/ml
8.  
 
The strongyles used for this present work 
are from a mixed infection naturally acquired 
by sheep, and were identified to be 
Table 1: Comparison of the bioactivity of 
ivermectin injection brands with Ivomec super. 
 
Injection brands LC50 (ng/ml) p-value 
1. Ivomec super 1.1±0.2*  
2. Iverject 2.3±0.3 < 0.01 
3. Ivermectin 3.00±0.3 < 0.01 
4. Kepromec 8.0±0.2 < 0.01 




























Figure 1: Linear relationship between mean values 
of live L3 (on a probit) of strongyles following a 7 day 
incubation period in ivermectin injection brands and 
ivermectin  concentration. Each point represents the 
mean of three replicates. 
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predominantly H. contortus. Ivomec MSD is 
the innovator company’s brand and it 
showed the highest activity (LC50 = 1.1 
ng/ml). However, it contains clorsulon in 
addition to the ivermectin active ingredient. 
The latter is reported (in the package insert) 
to be specific anthelmintic for liver fluke. It is 
possible that this combination could enhance 
the activity of ivermectin against other 
nematodes.  
 
Ivomec super was selected as the reference 
brand for estimating bioactivity of the other 
brands because it is the innovator brand. 
When compared with other products, the 
LC50 for Ivomec super was significantly 
different (p < 0.01). This implies that the 
bioactivity of this product is significantly 
different from this reference product. Results 
of this study could explain the variation in 
treatment response often reported by 
clinicians prescribing these different brands 
of ivermectin. Significant difference in the 
bioactivity of the brands is a reflection of the 
difference in the quality these drug products 
being marketed by different manufacturers. 
The biologic inequivalence of the different 
brands shown by this in vitro study could be 
due to differences in the formulation of the 




The results of this study show that the 
brands of ivermectin injection investigated 
are not bioequivalent. This could explain why 
different brands of ivermectin injection may 











An investigation of the chemical equivalence 
of the brands by a physicochemical assay 
method is warranted in order to provide 
supportive data that could further explain the 
differences in the LC50 obtained. The results 
underscore the need for post market 
surveillance of drugs intended for veterinary 





1. Turner MJ, Schaeffer JM. Mode of action of 
Ivermectin. In: Campbell WC (ed).  Ivermectin 
and Abamectin. New York, USA:  Springer, 
1989 pp 73-8. 
2. Campbell WC, Fisher MH, Stapley EO, Albert-
Schonberg G, Jacobs TA. Ivermectin: a potent 
new antiparasitic agent. Science. 1983:  22: 
823-8.  
3. Prichard RK.  Interaction of host physiology and 
efficacy of antiparasitic drug. Vet Parasitol. 
1985; 18: 103-10. 
4. Hubert J, Kerboeuf, D  " Nutritive medium for in-
vitro culture of Nematode larvae. Can J Comp 
Med. 1984; 48: 63. 
5. Bailey NTJ. Statistical Methods in Biology, 2nd ed. 
Cambridge, UK: Cambridge University Press, 
1981 pp 90-8. 
6. Ademola IO. A survey on ivermectin resistance in 
strongyles of sheep in Oyo Sate, Nigeria using 
Larval Development Assay. Israel J Vet Med. 
2002: 57(4): 149-51. 
7. Hubert J, Kerboeuf D. A microlarval development 
assay for the detection of anthelmintic 
resistance in sheep nematodes. Vet Record. 
1992; 130: 442-6. 
8. Taylor MA. A larval development tests for the 
detection anthelmintic resistance in nematode 
of sheep. J Vet Sci. 1990; 49: 198-202 
 
 
